Physician Assistant in Kingman, KS Accepting Medicare

7 Physician Assistant nurses found. Showing 1 - 7

Tyler J Antenen, P.A.-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 750 W D Ave, Kingman, KS 67068 Phone: 620-532-0295    Fax: 855-483-0002

Mr. Jeffery Leonard Henderson, PA-C Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 701 E A Ave, Kingman, KS 67068 Phone: 620-532-5145    Fax: 620-532-2586

Dennis Kalmar, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 750 W D Ave, Kingman, KS 67068 Phone: 620-532-0295    Fax: 855-483-0002

Mr. Carl Lee Green, P.A. Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 750 W D Ave, Kingman, KS 67068 Phone: 620-532-3147

Paul Halderson, Physician Assistant Medicare: Medicare Enrolled Practice Location: 750 W D Ave, Kingman, KS 67068 Phone: 620-532-3147    Fax: 620-532-0167

Kathryn A Kimpler, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 701 E A Ave, Kingman, KS 67068 Phone: 620-532-5145    Fax: 620-532-2478

Mr. Leroy E Shugart, P.A. Physician Assistant Medicare: Medicare Enrolled Practice Location: 750 W D Ave, Kingman, KS 67068 Phone: 620-532-3147    Fax: 620-532-3147

News Archive

Advanced breast cancer that has spread to the brain could be treated with drug combination

The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological side effects of whole brain radiotherapy (WBRT), suggests new research published Online First in The Lancet Oncology.

Centrifugal concentrators for biological applications

In this interview, Alison Wake from Genevac, discusses the use of centrifugal concentraters in biological research, and the miVac range provided by Genevac.

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

Diabetic neuropathy highly prevalent among diabetic patients in Romania

A survey of 25,000 Romanians with diabetes has revealed that diabetic neuropathy (DN), a complication of diabetes, is highly prevalent in these patients, even in the absence of a diagnostic, and has an important impact on patients' quality of life.

AMDL submits data to FDA for clearance to market its diagnostic test to monitor colorectal cancer patients

AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.

Read more Medical News

› Verified 5 days ago